Alexandra Karadimou
Overview
Explore the profile of Alexandra Karadimou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sofianidi A, Karadimou A, Charpidou A, Syrigos K
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473268
Lung cancer treatment and patient care are constantly improving, but it remains doubtful whether this applies equally to all socioeconomic groups. It is nowadays well established that there are socioeconomic...
2.
Mountzios G, Koumarianou A, Linardou H, Boutis A, Mavroudis D, Samantas E, et al.
Anticancer Res
. 2023 Apr;
43(5):2243-2258.
PMID: 37097667
Background/aim: Real-world data on the EGFR mutational profile upon progression after first/second-generation EGFR-TKI treatment in patients with advanced non-small-cell lung cancer (NSCLC) and treatment strategies employed thereon are needed. Patients...
3.
Hans S, Karadimou A, Mulvihill J, Grabrucker A, Zabetakis I
Biomedicines
. 2022 Dec;
10(12).
PMID: 36552006
Neurodegenerative diseases are a group of disorders characterised by progressive loss of brain function. The most common of these is Alzheimer's disease, a form of dementia. Intake of macro- and...
4.
Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al.
Clin Cancer Res
. 2015 Jan;
21(6):1329-39.
PMID: 25583177
Purpose: Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from treatment with targeted tyrosine kinase inhibitors (TKI) is a challenge. Our aim was to identify molecular...
5.
Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, et al.
Acta Oncol
. 2014 May;
53(10):1413-22.
PMID: 24874929
Unlabelled: There is growing evidence that sunitinib plasma levels have an impact on treatment outcome in patients with metastatic renal cell carcinoma (mRCC). We studied the impact of single nucleotide...
6.
Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, et al.
BMC Cancer
. 2014 Mar;
14:149.
PMID: 24593195
Background: Chemokine receptor signaling pathways are implicated in the pathobiology of renal cell carcinoma (RCC). However, the clinical relevance of CXCR2 receptor, mediating the effects of all angiogenic chemokines, remains...
7.
Beuselinck B, Vano Y, Oudard S, Wolter P, De Smet R, Depoorter L, et al.
BJU Int
. 2013 Nov;
114(1):81-9.
PMID: 24215209
Objective: To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Patients And Methods: We reviewed...
8.
Karadimou A, Lianos E, Pectasides D, Dimopoulos M, Bamias A
Open Access J Urol
. 2013 Nov;
2:193-9.
PMID: 24198628
Objective: Second-line treatment options in advanced urothelial cancer are limited. We investigated the efficacy of a methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) combination after failure of gemcitabine/platinum chemotherapy. Patients And Methods: Twenty-five patients with...
9.
Karadimou A, Dimopoulos M, Bamias A
Open Access J Urol
. 2013 Nov;
2:25-30.
PMID: 24198610
Testicular cancer is a highly curable neoplasm, even in the case of extragonadal disease. Nevertheless, patients with adverse prognostic features or relapsing after first-line cisplatin-based chemotherapy have a worse prognosis...
10.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al.
Acta Oncol
. 2013 Feb;
53(1):103-12.
PMID: 23421954
Background: There are no validated markers that predict outcome in metastatic renal cell cancer (mRCC) patients treated with sunitinib. Recently, single nucleotide polymorphism (SNP) rs9582036 in VEGFR1 has been proposed...